Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial

Pharmacology, Toxicology and Pharmaceutical Science

• Interleukin 6 100%
• Randomized Clinical Trial 100%
• Hydroxychloroquine 100%
• Antiplatelet 100%
• Receptor Antagonist 100%
• Lopinavir Plus Ritonavir 100%
• Hydrocortisone 50%
• Antiviral Drug 50%
• Antithrombocytic Agent 50%

Medicine and Dentistry

• Randomized Clinical Trial 100%
• Hazard Ratio 100%
• COVID-19 100%
• Interleukin 6 18%
• Hydroxychloroquine 18%
• Anticoagulation 18%
• Antiplatelet 18%
• Receptor Antagonist 18%
• Lopinavir/Ritonavir 18%
• Immunity 9%
• Treatment Effect 9%
• Hydrocortisone 9%
• Antiviral Drug 9%
• Antiplatelet Drug 9%

Nursing and Health Professions

• Hazard Ratio 100%
• Interleukin 6 18%
• Receptor 18%
• Anticoagulation 18%
• Hydroxychloroquine 18%
• Lopinavir Plus Ritonavir 18%
• Antithrombocytic Agent 9%
• Hydrocortisone 9%